Medication safety
Mekinist
Generic name: TRAMETINIB
Manufacturer: Novartis Pharmaceuticals Corporation
When to use
1 INDICATIONS AND USAGE MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma…
Dosage and administration
2 DOSAGE AND ADMINISTRATION The recommended dosage of MEKINIST in adult patients is 2 mg orally once daily. The recommended dosage for MEKINIST in pediatric patients is based on body weight. ( 2 ) 2.1 Patient Selection Melanoma Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of treatment with MEKINIST as a single agent or in combination with dabrafenib…
Looking for a provider?
Search for providers who may prescribe or administer this medication, or find a community clinic for lower-cost care.
Drug information is sourced from openFDA and is for educational purposes. It does not replace medical advice from a licensed professional. Always consult your healthcare provider before taking any medication.